L3VLUP
ProSign in

BBIO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BBIOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BBIO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBBIOLLY
Q3 20204 holders, $1.1bn33 holders, $14.1bn
Q4 20205 holders, $2.0bn29 holders, $17.3bn
Q1 20215 holders, $1.9bn24 holders, $23.0bn
Q2 20215 holders, $1.8bn24 holders, $27.8bn
Q3 20214 holders, $1.4bn31 holders, $29.9bn
Q4 20212 holders, $452m31 holders, $34.7bn
Q1 20222 holders, $276m24 holders, $35.3bn
Q2 20222 holders, $246m33 holders, $42.7bn
Q3 20223 holders, $271m31 holders, $43.4bn
Q4 20222 holders, $204m31 holders, $46.6bn
Q1 20234 holders, $477m33 holders, $44.3bn
Q2 20232 holders, $463m37 holders, $59.6bn
Q3 20239 holders, $898m44 holders, $67.6bn
Q4 20239 holders, $1.3bn45 holders, $73.6bn
Q1 20247 holders, $1.1bn41 holders, $95.3bn
Q2 20244 holders, $826m43 holders, $110bn
Q3 20248 holders, $927m45 holders, $107bn
Q4 20247 holders, $1.2bn46 holders, $93.9bn
Q1 20259 holders, $1.6bn42 holders, $98.4bn
Q2 202515 holders, $2.3bn43 holders, $93.2bn
Q3 202514 holders, $2.3bn39 holders, $86.7bn
Q4 202518 holders, $4.3bn41 holders, $123bn
Q1 202620 holders, $4.4bn39 holders, $106bn
Q2 202618 holders, $4.5bn44 holders, $132bn
BBIO

Bridgebio Pharma Inc

Holders
14
Reported value
$2.3bn
Buyers
5
Sellers
9

Breadth -4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BBIO (2)

Farallon Capital Management LLC, Viking Global Investors LP

Only LLY (27)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Walleye Capital LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →